Biotech company Amgen (NASDAQ: AMGN) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 8.5% year on year to $10.37 billion. The company’s full-year revenue guidance of $39.3 billion at the midpoint came in 0.8% above analysts’ estimates. Its non-GAAP profit of $6.45 per share was 11.6% above analysts’ consensus estimates.
Is now the time to buy AMGN? Find out in our full research report (it’s free for active Edge members).
Amgen (AMGN) Q3 2026 highlights:
- Revenue $10.37 billion vs S&P analysts’ estimates of $10.05 billion (8.5% year-on-year growth, 3.1% beat)
- Adjusted EPS $6.45 vs S&P analysts’ estimates of $5.78 (11.6% beat)
- Adjusted operating income $4.68 billion vs analyst estimates of $4.31 billion (45.1% margin, 8.6% beat)
- Revenue guidance The company lifted its revenue guidance for the full year to $39.3 billion at the midpoint from $38.8 billion, a 1.3% increase
- Adjusted EPS guidance Management raised its full-year adjusted EPS guidance to $23.30 at the midpoint, a 1.7% increase
- Operating margin 35.8%, up from 26.4% in the same quarter last year
- Market capitalization $249.4 billion
StockStory’s take
Amgen’s latest quarter reflected broad-based strength across its key therapeutic franchises, with management crediting double-digit growth from six core products and strong execution in commercial operations. CEO Bob Bradway highlighted that 17 products now annualize at over $1 billion in sales, underscoring both portfolio depth and sustained demand. The quarter’s performance was further shaped by strong clinical progress in late-stage pipeline candidates, with positive trial results in oncology and immunology noted as important contributors. Management emphasized continued R&D investment and highlighted the company’s ability to address large, under-treated patient populations, particularly in cardiovascular and inflammatory diseases.
Looking forward, Amgen’s updated outlook is supported by expectations for continued expansion of its growth drivers and the advancement of new therapies. Management pointed to the potential of first-in-class and best-in-class medicines, such as IMDELLTRA in small cell lung cancer and MariTide for obesity, to shape future performance. CFO Thomas Dittrich emphasized ongoing investments in manufacturing and R&D to support new launches, while Murdo Gordon, executive vice president of Global Commercial Operations, stressed the opportunity to reach additional patients through market expansion and new indications. The company remains focused on pipeline execution and regulatory milestones to sustain long-term growth.
Key insights from management’s remarks
Management attributed the quarter’s results to substantial sales expansion in core products, enhanced adoption of new therapies, and clinical progress in late-stage programs.
- Repatha momentum accelerates: Amgen saw significant uptake for Repatha, driven by updated clinical guidelines and cardiovascular outcomes data. The drug’s adoption in both primary and secondary prevention of cardiovascular events is expanding, with management citing deeper conviction among prescribers and increased use in primary care.
- EVENITY and osteoporosis franchise: EVENITY posted strong growth, benefiting from an expanded prescriber base and deeper penetration among high-risk osteoporosis patients. Management noted its leadership in the Japanese market and continued investment to broaden U.S. adoption.
- TEZSPIRE outperforms asthma market: TEZSPIRE’s growth exceeded the overall severe asthma market, capturing increasing share among allergists and pulmonologists. Positive phase III results in eosinophilic esophagitis were highlighted as a platform for future indication expansion.
- Rare disease and UPLIZNA expansion: The rare disease portfolio delivered robust growth, especially UPLIZNA, which saw broad adoption in generalized myasthenia gravis and international markets. Durable efficacy and favorable dosing supported wider use and patient retention.
- IMDELLTRA establishes new oncology standard: IMDELLTRA’s strong clinical and commercial performance in small cell lung cancer was a focal point, with recent trial results demonstrating significant survival benefits and reduced monitoring requirements, positioning it as a potential cornerstone therapy for earlier disease stages.
Drivers of future performance
Amgen’s forward outlook is shaped by advancing late-stage pipeline candidates, broadening product indications, and disciplined investment in R&D and manufacturing.
- Pipeline launches and regulatory milestones: The company expects upcoming data readouts and regulatory filings for key programs—such as MariTide for obesity and dazodalibep for Sjögren’s disease—to be pivotal in driving both near- and long-term revenue growth. Management believes first-in-class therapies will expand Amgen’s addressable markets.
- Market expansion and new indications: Management is focused on accelerating growth by reaching under-penetrated patient populations and securing additional indications for core products. For example, the expansion of TEZSPIRE into conditions beyond asthma and the anticipated launch of IMDELLTRA in earlier lines of small cell lung cancer treatment are expected to increase patient reach.
- Manufacturing and operational investments: Ongoing capital expenditures aim to scale capacity for anticipated product launches, particularly for MariTide, while maintaining supply chain reliability for existing therapies and biosimilars. Management flagged that operational discipline and expense management will be critical to sustaining profit margins during this growth phase.
Catalysts in upcoming quarters
In the coming quarters, the StockStory team will monitor (1) the pace of regulatory submissions and data readouts for late-stage pipeline assets like MariTide and dazodalibep, (2) evidence of further adoption and market share gains for IMDELLTRA and TEZSPIRE in new indications, and (3) progress in scaling manufacturing capacity to support new launches. Continued execution in expanding access to under-treated patient populations will also be a key signpost.
Amgen currently trades at $455.75, down from $461.26 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).
Our favorite stocks right now
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
